With the growth of comparative effectiveness research (CER) and the need for large volumes of active comparator medicines comes an increased demand for effective sourcing and distribution of investigational medicinal products (IMPs). Mark Ware, Global Head of Business Development and Strategic Services at Clinigen Clinical Trial Services, explores how specialist sourcing companies are responding to the evolving needs of their customers in order to provide strategic comparator medicines supply and distribution.